- Home
- STAA vs MLTX Comparison
STAA vs MLTX Comparison
Compare STAA & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STAA | MLTX |
|---|---|---|
| Founded | 1982 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STAA | MLTX |
|---|---|---|
| Price | $29.00 | $19.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | $22.81 | ★ $27.50 |
| AVG Volume (30 Days) | 640.9K | ★ 722.7K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $239,442,000.00 | N/A |
| Revenue This Year | $30.82 | N/A |
| Revenue Next Year | $8.41 | N/A |
| P/E Ratio | $288.85 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.59 | $5.95 |
| 52 Week High | $35.87 | $62.75 |
Technical Indicators
Market Signals| Indicator | STAA | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.23 | 58.60 |
| Support Level | $28.03 | $15.54 |
| Resistance Level | $31.05 | $19.24 |
| Average True Range (ATR) | 1.00 | 0.92 |
| MACD | -0.28 | 0.10 |
| Stochastic Oscillator | 36.09 | 70.72 |
Price Performance
Historical ComparisonAbout STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.